Combination of conserved recombinant proteins (NP & 3M2e) formulated with Alum protected BALB/c mice against influenza A/PR8/H1N1 virus challenge
- PMID: 34491470
- DOI: 10.1007/s10529-021-03174-2
Combination of conserved recombinant proteins (NP & 3M2e) formulated with Alum protected BALB/c mice against influenza A/PR8/H1N1 virus challenge
Abstract
Purpose: Influenza is one of the most important agents of pandemic outbreak causing substantial morbidity and mortality. Vaccination strategies of influenza must be adapted annually due to constant antigenic changes in various strains. Therefore, the present study was conducted to evaluate protective immunity of the conserved influenza proteins.
Methods: For this purpose, three tandem repeats of M2e (3M2e) and NP were separately expressed in E. coli and were purified using column chromatography. Female Balb/c mice were injected intradermally with a combination of the purified 3M2e and NP alone or formulated with Alum (AlOH3) adjuvant in three doses. The mice were challenged by intranasal administration of H1N1 (A/PR/8/34) 2 weeks after the last vaccination.
Results: The results demonstrated that recombinant NP and M2e proteins are immunogenic and could efficiently elicit immune responses in mice compared to non-immunized mice. The combination of 3M2e and NP supplemented with Alum stimulated both NP and M2e-specific antibodies, which were higher than those stimulated by each single antigen plus Alum. In addition, the secretion of IFN-γ and IL-4 as well as the induction of lymphocyte proliferation in mice received the mixture of these proteins with Alum was considerably higher than other groups. Moreover, the highest survival rate (86%) with the least body weight change was observed in the mice immunized with 3M2e and NP supplemented with Alum followed by the mice received NP supplemented with Alum (71%).
Conclusion: Accordingly, this regimen can be considered as an attractive candidate for global vaccination against influenza.
Keywords: Influenza virus; M2e; NP; Recombinant protein; Universal vaccine.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.
Similar articles
-
Influenza Chimeric Protein (3M2e-3HA2-NP) Adjuvanted with PGA/Alum Confers Cross-Protection against Heterologous Influenza A Viruses.J Microbiol Biotechnol. 2021 Feb 28;31(2):304-316. doi: 10.4014/jmb.2011.11029. J Microbiol Biotechnol. 2021. PMID: 33263336 Free PMC article.
-
Vaccination with three tandem repeats of M2 extracellular domain fused to Leismania major HSP70 protects mice against influenza A virus challenge.Virus Res. 2018 Jun 2;251:40-46. doi: 10.1016/j.virusres.2018.05.003. Epub 2018 May 3. Virus Res. 2018. PMID: 29730305
-
Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge.Antiviral Res. 2013 Apr;98(1):4-11. doi: 10.1016/j.antiviral.2013.01.010. Epub 2013 Feb 14. Antiviral Res. 2013. PMID: 23416215
-
Influenza Antigens NP and M2 Confer Cross Protection to BALB/c Mice against Lethal Challenge with H1N1, Pandemic H1N1 or H5N1 Influenza A Viruses.Viruses. 2021 Aug 27;13(9):1708. doi: 10.3390/v13091708. Viruses. 2021. PMID: 34578289 Free PMC article.
-
Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.Virol Sin. 2019 Oct;34(5):583-591. doi: 10.1007/s12250-019-00138-9. Epub 2019 Jun 25. Virol Sin. 2019. PMID: 31240620 Free PMC article.
References
-
- Awate S, Babiuk L, Mutwiri G (2013) Mechanisms of action of adjuvants. Front Immunol 4:114 - DOI
-
- Bernelin-Cottet C, Deloizy C, Stanek O, Barc C, Bouguyon E, Urien C, Da Costa B (2016) A universal influenza vaccine can lead to disease exacerbation or viral control depending on delivery strategies. Front Immunol 7:641 - DOI
-
- Bernstein ED, Gardner EM, Abrutyn E, Gross P, Murasko DM (1998) Cytokine production after influenza vaccination in a healthy elderly population. Vaccine 16:1722–1731 - DOI
-
- Carragher D, Kaminski D, Moquin A, Hartson L, Randall T (2008) A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol Res 181:4168–4176
-
- De Filette M, Fiers W, Martens W, Birkett A, Ramne A, Löwenadler B, Saelens X (2006a) Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 24:6597–6601 - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous